Medication infusion components and systems
US12201752B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 12, 2021 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | Sep 13, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M2230/201
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.